A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia
Phase of Trial: Phase II/III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 19 Jun 2017 Planned End Date changed from 16 Oct 2017 to 16 Mar 2018.
- 19 Jun 2017 Planned primary completion date changed from 16 Oct 2017 to 16 Mar 2018.
- 16 May 2017 Status changed from not yet recruiting to recruiting.